Sign In
Buy NPCE
$12.89
-0.86 (-6.25%)
At Close: Jul 31, 2026
NeuroPace Strengthens Management Team with Two Key Appointments
04:05pm, Wednesday, 04'th Sep 2024
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice Presi
NeuroPace Announces Participation at Two Upcoming Healthcare Investor Conferences
04:05pm, Tuesday, 27'th Aug 2024
MOUNTAIN VIEW, Calif., Aug. 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it w
NeuroPace to Participate in Upcoming Healthcare Conferences in September
04:05pm, Thursday, 22'nd Aug 2024
MOUNTAIN VIEW, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it w
NeuroPace: Only For Those With Strong Nerves
01:01pm, Tuesday, 20'th Aug 2024
NeuroPace, Inc. aims to improve the lives of epilepsy patients with RNS technology, addressing drug-resistant epilepsy. The company has seen revenue growth, but continues to post losses nonetheless. N
NeuroPace (NPCE) Q2 Earnings Beat, '24 Sales View Up
08:40am, Tuesday, 20'th Aug 2024
NeuroPace's (NPCE) top and bottom lines outpace estimates in the second quarter.
NeuroPace, Inc. (NPCE) Q2 2024 Earnings Call Transcript
10:22pm, Tuesday, 13'th Aug 2024
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Office
NeuroPace to Report Second Quarter 2024 Financial Results on August 13, 2024
04:05pm, Tuesday, 23'rd Jul 2024
MOUNTAIN VIEW, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it w
NeuroPace, Inc. (NPCE) Q1 2024 Earnings Call Transcript
09:08am, Sunday, 12'th May 2024
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Jeremy Feffer - Managing Director, LifeSci Advisors Joel Becker - Chief Executive Officer Re
NeuroPace Reports First Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Wednesday, 08'th May 2024
-- Revenue increased to $18.1 million in Q1 2024, a 25% increase over Q1 2023 -- -- Extended the maturity date of the Company's term loan by one year to September 30, 2026 --
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
04:05pm, Wednesday, 17'th Apr 2024
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
04:05pm, Wednesday, 27'th Mar 2024
MOUNTAIN VIEW, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it
NeuroPace, Inc. (NPCE) Q4 2023 Earnings Call Transcript
09:29pm, Tuesday, 05'th Mar 2024
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Conference Call March 5, 2024 4:30 PM ET
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
04:05pm, Tuesday, 05'th Mar 2024
-- Revenue increased to $18.0 million in Q4 2023, a 41% increase over Q4 2022 -- -- Revenue increased to $65.4 million in 2023, a 44% increase over 2022 --
Financial Freedom Fighters: 3 Stocks to Liberate Your Portfolio
02:00pm, Tuesday, 05'th Mar 2024
One of the best stocks for financial freedom over the past 30 years is Monster Beverage (NASDAQ: MNST ). Between Feb. 14, 1994, and Feb. 14, 2024, the energy drink maker's stock appreciated around 200
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
04:05pm, Thursday, 15'th Feb 2024
MOUNTAIN VIEW, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, tod
